Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ensysce Biosciences (LACQ) stocks in Canada

Learn how to easily invest in Ensysce Biosciences stocks.

Ensysce Biosciences is a shell companies business based in the US. Ensysce Biosciences stocks (LACQ.US) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $14.45 – an increase of 2.97% over the previous week. Ensysce Biosciences employs 0 staff and has a market cap (total outstanding stock value) of $90.2 million.

How to buy shares in Ensysce Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LACQ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ensysce Biosciences stock price (PINK:LACQ)

Use our graph to track the performance of LACQ stocks over time.

Ensysce Biosciences shares at a glance

Information last updated 2021-07-31.
Latest market close$13.85
52-week range$11.01 - $23.99
50-day moving average $13.97
200-day moving average $13.65
Wall St. target priceN/A
PE ratio 118.7705
Dividend yield N/A (0%)
Earnings per share (TTM) $0.12

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Ensysce Biosciences price performance over time

Historical closes compared with the close of $13.85 from 2021-05-28

1 week (2022-01-05) N/A
1 month (2021-12-12) N/A
3 months (2021-10-12) N/A
6 months (2021-07-12) N/A
1 year (2021-01-15) 11.07%
2 years (2020-01-16) 32.92%
3 years (2019-01-12) N/A
5 years (2017-01-12) N/A

Is Ensysce Biosciences under- or over-valued?

Valuing Ensysce Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ensysce Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ensysce Biosciences's P/E ratio

Ensysce Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Ensysce Biosciences shares trade at around 119x recent earnings.

Ensysce Biosciences financials

Gross profit TTM $0
Return on assets TTM -1.25%
Return on equity TTM 23.4%
Profit margin 0%
Book value $0.30
Market capitalisation $90.2 million

TTM: trailing 12 months

Ensysce Biosciences share dividends

We're not expecting Ensysce Biosciences to pay a dividend over the next 12 months.

Ensysce Biosciences share price volatility

Over the last 12 months, Ensysce Biosciences's shares have ranged in value from as little as $11.01 up to $23.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Ensysce Biosciences's is -0.1134. This would suggest that Ensysce Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ensysce Biosciences has bucked the trend.

Ensysce Biosciences overview

Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California. .

Frequently asked questions

Ensysce Biosciences in the news

There are no recent company news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site